SecBot SecBot
PRESS-RELEASE ·Filed Nov 9, 2026

HRTX

Heron Therapeutics, Inc.
MIXED
Impact 7/10
Horizonmonths Processed7d 20h ago WireGlobeNewswire
Press release · M&A
Actionable Insight ◆ Mixed

Watch for Heron stockholder vote and HSR clearance in Q1 2027. Heron's post-close strategy (use of NOLs, potential new acquisitions) and CRMD's integration execution (synergy realization, ZYNRELEF growth) will determine long-term value. The Pharmakon facility's second $75M tranche signals further M&A appetite.

DirectionMixed
Confidencehigh
Horizonmonths

Drugs in focus

HRTX drug pipeline →

APONVIE

● Neutral Named in this press release
Impact
Phase
Approved
Time to market
Already approved and commercially available since March 2023.
Next catalyst
None dated

What to watchAPONVIE is now part of the CorMedix asset acquisition announced November 9, 2026. The deal is expected to close in Q1 2027. For Heron shareholders, the stock's value will increasingly reflect the CRMD shares and NOLs Heron retains post-close rather than APONVIE's standalone commercial trajectory. For CorMedix, APONVIE adds a growing hospital antiemetic to its institutional portfolio.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$0.3706
T+0 close · Nov 9, 2026 · via day close
Latest settled
−23.29%
T+5 · $0.2843
Vs SPY
−21.59%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $0.3706entry
  2. T+1 · 7d ago +0.94%α +1.31% · $0.3741
  3. T+5 · 21h ago −23.29%α −21.59% · $0.2843
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CorMedix (CRMD) will acquire substantially all of Heron Therapeutics' (HRTX) assets for $145M cash plus 14.6M CRMD shares (worth ~$77.6M at signing), plus up to $55M in earn-outs and royalties. The deal adds four commercial-stage hospital products (ZYNRELEF, APONVIE, CINVANTI, SUSTOL) to CorMedix's institutional platform. Heron will remain a public company with CRMD stock, NOLs (~$2.3B), and earn-out rights, while repaying its Hercules credit facility. The transaction is expected to close in Q1 2027.

Key Financial Metrics

Deal Value
$222.6M

Key Facts

  • Upfront consideration: $145M cash plus 14,583,333 shares of CorMedix common stock (fixed at $7.20/share, valued at ~$77.6M at CRMD's $5.32 closing price on Nov 6, 2026), aggregate ~$222.6M
  • Additional earn-out: up to $55M tied to ZYNRELEF 2028 net sales ($25M if ≥$65M, +$30M if ≥$95M)
  • 5% royalty on combined annual net sales of CINVANTI, SUSTOL, and licensed products exceeding $25M in 2027-2029
  • CorMedix expects $45-$60M in near-term operating cost synergies by year-end 2027
  • Transaction immediately accretive to CorMedix earnings and free cash flow
  • Heron will repay its Hercules credit facility, retain ~$2.3B in NOLs, and become a significant CRMD stockholder
  • Rubric Capital Management will exchange $35M principal plus accrued interest (~$37.8M total) of Heron convertible notes for CRMD shares in four quarterly tranches post-closing
  • Heron stockholders holding ~22% of shares (including Rubric) have agreed to vote in favor
  • CorMedix entered a $150M senior secured term loan facility with Pharmakon Advisors; $75M drawn at closing, $75M optional tranche through June 2028
  • Transaction subject to Heron stockholder approval, HSR clearance, and other conditions; no financing contingency

Financial Impact

Upfront consideration ~$222.6M (cash + stock), plus up to $55M earn-outs and royalties; CorMedix expects pro forma 2026 revenue of $465-$490M and $45-$60M in synergies

revenueearningsdebtdilution

Risk Factors

  • Heron stockholder approval not guaranteed; 22% committed but remaining 78% may vote no
  • HSR antitrust review could delay or block the transaction
  • Integration risk: achieving $45-$60M synergies and maintaining product revenue
  • ZYNRELEF earn-out thresholds ($65M and $95M in 2028 net sales) may not be met
  • Heron's post-close public company status with no operating revenue and reliance on CRMD stock value creates uncertainty
  • Rubric exchange of convertible notes for CRMD shares could create overhang if sold

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3398281

Track record

15 reports on HRTX

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +58.33% at T+20 after the May 11, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 9, 20267d ago DEFA14A Neutral 6/10 Entry $0.3741 Now $0.2800 −25.15% settles Feb 8
  2. Nov 9, 20267d ago DEFA14A Neutral 6/10 Entry $0.3706 Now $0.2800 −24.45% settles Feb 5
  3. Nov 9, 20267d ago 8-K Neutral 6/10 Entry $0.3706 Now $0.2800 −24.45% settles Feb 5
  4. Nov 9, 20267d ago 8-K Neutral 6/10 Entry $0.3706 Now $0.2800 −24.45% settles Feb 5
  5. Nov 9, 20267d ago Press Release Mixed 7/10 Viewing Entry $0.3706 Now $0.2800 −24.45% settles Feb 5
  6. Aug 10, 202614w ago 8-K Bearish 7/10 No price data
  7. Aug 10, 202614w ago Press Release Bearish 7/10 Entry $0.3350 to $0.2847 Now $0.2800 +16.42% ▲ +15.01% +12.60% vs SPY
  8. Jun 25, 202620w ago 8-K Bearish 7/10 Entry $0.4300 to $0.2700 Now $0.2800 +34.88% ▲ +37.21% +43.31% vs SPY
  9. Jun 2, 202623w ago 8-K Bearish 7/10 Entry $0.4500 to $0.3321 Now $0.2800 +37.78% ▲ +26.20% +28.70% vs SPY
  10. May 11, 202627w ago 8-K Bearish 6/10 No price data
Showing 10 of 15

US Market Status

Market Closed · Opens in 5h 17m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026